Chẩn đoán Lymphoma Hodgkin — tình hình hiện tại

Coller BS, Chabner BA, Gralnick HR (1977) Frequencies and patterns of bone marrow involvement in non-Hodgkin lymphomas: observations on the value of bilateral biopsies. Am J Hematol 3:105–119 de Wit M, Bohuslavizki KH, Buchert R, Bumann D, Clausen M, Hossfeld DK (2001) 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin’s lymphoma. Ann Oncol 12:29–37 Deutsche Hodgkin-Lymphom-Studiengruppe (2004) HD15 für fortgeschrittene Stadien. Qualitätssicherungsprotokoll zur Toxizitätsreduktion und zur prognostischen Bedeutung der FDG-PET in der Primärtherapie des fortgeschrittenen Morbus Hodgkin (8 × BEACOPP eskaliert vs. 6 × BEACOPP eskaliert vs. 8 × BEACOPP-14, gefolgt von RT auf PET positive PR), 3. Aufl., Köln Dietlein M, Schicha H (2003) Vergütung der PET in der Onkologie in Europa: Eine Umfrage. Nuklearmedizin 42:80–85 Dittmann H, Sökler M, Kollmannsberger C et al. (2001) Comparison of18FDG-PET with CT-Scans in the evaluation of patients with residual and recurrent Hodgkin’s lymphoma. Oncol Rep 8:1393–1399 Eich HT, Staar S, Gossmann A et al. (2004) German Hodgkin Lymphoma Study Group. The HD12 panel of the German Hodgkin Lymphoma Study Group (GHSG): a quality assurance program based on a multidisciplinary panel reviewing all patients‘ imaging. Am J Clin Oncol 27:279–284 Fishman EK, Kuhlman JE, Jones RJ (1991) CT of lymphoma: spectrum of disease. Radiographics 11:647–669 Guermazi A, Brice P, de Kerviler EE, Ferme C, Hennequin C, Meignin V, Frija J (2001) Extranodal Hodgkin disease: spectrum of disease. Radiographics 21:161–179 Harisinghani MG, Saini S, Weissleder R, Hahn PF, Yantiss RK, Tempany C, Wood BJ, Mueller PR (1999) MR lymphangiography using ultrasmall superparamagnetic iron oxide in patients with primary abdominal and pelvic malignancies: radiographic-pathologic correlation. AJR Am J Roentgenol 172:1347–1351 Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, de la Rosette J, Weissleder R (2003) Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348:2491–2499 Hutchings M, Eigtved A, Specht L (2004) Early prediction of chemotherapy treatment response in Hodgkin lymphoma with positron emission tomography. Eur J Haematol 73 [Suppl 65]:29 Jerusalem G, Beguin Y, Fassotte MF, Belhocine T, Hustinx R, Rigo P, Fillet G (2003) Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin’s disease. Ann Oncol 14:123–130 Jung G, Heindel W, von Bergwelt-Baildon M, Bredenfeld H, Gossmann A, Zahringer M, Tesch H (200) Abdominal lymphoma staging: is MR imaging with T2-weighted turbo-spin-echo sequence a diagnostic alternative to contrast-enhanced spiral CT? J Comput Assist Tomogr 24:783–787 Kellenberger CJ, Epelman M, Miller SF, Babyn PS (2004) Fast STIR whole-body MR imaging in children. Radiographics 24:1317–1330 Kostakoglu L, Goldsmith SJ (2000) Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears? Eur J Nucl Med 27:1564–1578 Lauenstein TC, Goehde SC, Herborn CU, Goyen M, Oberhoff C, Debatin JF, Ruehm SG, Barkhausen J (2004) Whole-body MR imaging: evaluation of patients for metastases. Radiology 233:139–148 Linden A, Zankovich R, Theissen P, Diehl V, Schicha H (1989) Malignant lymphoma: bone marrow imaging versus biopsy. Radiology 173:335–339 Naumann R, Vaic A, Beuthien-Baumann B, Bredow J, Kropp J, Kittner T, Franke WG, Ehninger G (2001) Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin’s disease and non- Hodgkin’s lymphoma. Br J Haematol 115:793–800 Naumann R, Beuthien-Baumann B, Reiß A et al. (2004) Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin’s lymphoma. Br J Cancer 90:620–625 O’Doherty MJ, Barrington SF (2003) When is PET not useful in the assessment of lymphoma? [Editorial] Eur J Nucl Med Mol Imaging 30:1203–1204 Spaepen K, Stroobants S, Dupont P et al. (2001) Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin’s lymphoma: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 19:414–419 Spaepen K, Stroobants S, Dupont P et al. (2001) Can positron emission tomography with [18F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin’s disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 115:272–278 Steinborn MM, Heuck AF, Tiling R, Bruegel M, Gauger L, Reiser MF (1999) Whole-body bone marrow MRI in patients with metastatic disease to the skeletal system. J Comput Assist Tomogr 23:123–129 Walker R, Kessar P, Blanchard R et al. (2000) Turbo STIR magnetic resonance imaging as a whole-body screening tool for metastases in patients with breast carcinoma: preliminary clinical experience. J Magn Reson Imaging 11:343–350 Weihrauch MR, Re D, Scheidhauer K et al. (2001) Thoracic positron emission tomography using18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin’s disease. Blood 98:2930–2934 Weihrauch MR, Re D, Bischoff S et al. (2002) Whole-body positron emission tomography using18F-fluorodeoxyglucose for initial staging of patients with Hodgkin’s disease. Ann Hematology 81:20–25 Weihrauch MR, Dietlein M, Schicha H, Diehl V, Tesch H (2003) Prognostic significance of18F-fluorodeoxyglucose positron emission tomography in lymphoma. Leuk Lymphoma 44:15–22 Weissleder R, Elizondo G, Wittenberg J, Lee AS, Josephson L, Brady TJ (1990) Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology 175(2):494–498